The 2025 Pujiang Prostate Cancer Academic Congress was held from June 27–28 in Shanghai, in collaboration with the Annual Meeting of the CSCO Prostate Cancer Committee (CSCO-PC), the Prostate Cancer Conference of the CACA Genitourinary Oncology Committee (CACA-GO), and the Chinese Prostate Cancer Consortium (CPCC) Annual Meeting. Centered around the theme “Global Wisdom, Chinese Practice, Precision Breakthroughs,” the event brought together leading experts to discuss cutting-edge progress and clinical insights in prostate cancer care. In an exclusive interview with Oncology Frontier – Urology Frontier, Professor Xiaojian Qin of Fudan University Shanghai Cancer Center shared his views on how the guiding philosophy in prostate cancer treatment is evolving.

Editor’s Note: The 2025 Pujiang Prostate Cancer Academic Congress was held from June 27–28 in Shanghai, alongside the Annual Meeting of the CSCO Prostate Cancer Committee (CSCO-PC), the Prostate Cancer…

Editor’s Note: The 2025 Pujiang Prostate Cancer Academic Congress, held from June 27–28 in Shanghai, was organized in conjunction with the Annual Meeting of the CSCO Prostate Cancer Committee (CSCO-PC),…

On June 27, 2025, the Pujiang Prostate Cancer Academic Congress was held in Shanghai, in conjunction with the Annual Meeting of the Chinese Society of Clinical Oncology Prostate Cancer Committee (CSCO-PC), the Prostate Cancer Meeting of the CACA Genitourinary Oncology Committee (CACA-GO), and the Annual Meeting of the Chinese Prostate Cancer Consortium (CPCC). The event gathered leading experts from around the world to discuss cutting-edge developments in prostate cancer treatment. Professor Lu Yang, Department of Urology, West China Hospital of Sichuan University, delivered a keynote presentation on recent advances in targeting the androgen receptor (AR) pathway in prostate cancer, providing important insights for clinical decision-making. He offered a comprehensive overview of the latest innovations in monotherapy, emerging evidence from combination strategies, and the translational potential of new technologies such as PROTACs and epigenetic modulators—while also addressing current challenges and future directions.